Pub Date : 2018-06-11DOI: 10.29011/2574-7711.100066
J. Pérez‐Molina, Aleyda Carolina Barajas-Serrano, Andrés Palomera-Chávez, J. G. Panduro-Barón, N. Quezada-Figueroa, G. Yanowsky-Reyes, J. Orozco-Pérez
Citation: The Pregnancy-Specific Stress How Factor Risk for Preterm Abstract Preterm birth (PB) has a multifactorial etiology and psychosocial stress can be a risk factor. Objective. Quantify the as sociation of the specific stress of pregnancy with PB. Material and methods. A case-control study was conducted in 254 preterm mother-child dyads and 254 term dyads, between 2010 and 2011, at the Civil Hospital of Guadalajara. The dependent variable was PB (24-36 weeks of gestation) and the independent stress specific to pregnancy. Gestational age was confirmed with the Capurro and Ballard methods. The specific stress of pregnancy was sought by direct interview. We inquired about psychosocial, obstetric and illicit drugs. The association was evaluated with logistic regression. Results. The age of the mothers was 25 ± 6 years. The frequency of psychosocial factors and drug use was similar. In the bivariate analysis were more frequent in PB, antecedent of PB (OR: 1.98, CI95%: 1.17-3.36), diseases in pregnancy (OR: 1.49, CI95%: 1.03-2.17), multiple pregnancy (OR: 14.72, CI95%: 4.28-60.63), being born by caesarean section (OR: 4.93, CI95%: 3.26-7.48, worrying about work and family care (OR 1.60, CI95% 1.01-2.55) and paying for clothes, food and medical expenses of the baby (OR 1.55, CI95% 1.00-2.39). A multivariate model identified as covariates associated with PB to worry a lot about the care of the new baby (OR 2.58, CI95% 1.21-5.47) and to be born by caesarean section (OR 5.59, CI95% 2.63-11.90). Discussion and conclusion. Of the variables related to specific stress of pregnancy, only worry much about the care of the baby was associated with PB, as well as being born by cesarean section.
{"title":"The Pregnancy-Specific Stress How Factor Risk for Preterm Birth","authors":"J. Pérez‐Molina, Aleyda Carolina Barajas-Serrano, Andrés Palomera-Chávez, J. G. Panduro-Barón, N. Quezada-Figueroa, G. Yanowsky-Reyes, J. Orozco-Pérez","doi":"10.29011/2574-7711.100066","DOIUrl":"https://doi.org/10.29011/2574-7711.100066","url":null,"abstract":"Citation: The Pregnancy-Specific Stress How Factor Risk for Preterm Abstract Preterm birth (PB) has a multifactorial etiology and psychosocial stress can be a risk factor. Objective. Quantify the as sociation of the specific stress of pregnancy with PB. Material and methods. A case-control study was conducted in 254 preterm mother-child dyads and 254 term dyads, between 2010 and 2011, at the Civil Hospital of Guadalajara. The dependent variable was PB (24-36 weeks of gestation) and the independent stress specific to pregnancy. Gestational age was confirmed with the Capurro and Ballard methods. The specific stress of pregnancy was sought by direct interview. We inquired about psychosocial, obstetric and illicit drugs. The association was evaluated with logistic regression. Results. The age of the mothers was 25 ± 6 years. The frequency of psychosocial factors and drug use was similar. In the bivariate analysis were more frequent in PB, antecedent of PB (OR: 1.98, CI95%: 1.17-3.36), diseases in pregnancy (OR: 1.49, CI95%: 1.03-2.17), multiple pregnancy (OR: 14.72, CI95%: 4.28-60.63), being born by caesarean section (OR: 4.93, CI95%: 3.26-7.48, worrying about work and family care (OR 1.60, CI95% 1.01-2.55) and paying for clothes, food and medical expenses of the baby (OR 1.55, CI95% 1.00-2.39). A multivariate model identified as covariates associated with PB to worry a lot about the care of the new baby (OR 2.58, CI95% 1.21-5.47) and to be born by caesarean section (OR 5.59, CI95% 2.63-11.90). Discussion and conclusion. Of the variables related to specific stress of pregnancy, only worry much about the care of the baby was associated with PB, as well as being born by cesarean section.","PeriodicalId":23793,"journal":{"name":"World Academy of Science, Engineering and Technology, International Journal of Pharmacological and Pharmaceutical Sciences","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81292812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-02-12DOI: 10.21608/ejchem.2019.15114.1917
H. El-Rafie, A. Zeid, A. Sleem, Rs Mohammed
Acrocarpus is a genus of flowering plants in the legume family Fabaceae which considered as a large and economically important family. This study aimed to carry out the biological activity screening on the total ethanol and successive extracts of Acrocarpus fraxinofolius (A. fraxinofolius) bark, for the first time. The biological activity studied embraced, management of diabetes in alloxan induced diabetic rats, cytotoxic activity against four human tumor cell lines and hepatoprotective activity against CCl4-induced hepatotoxicity in rats and the activity was studied by assaying the serum marker enzymes like AST, ALT, and ALP. Concerning this, the petroleum ether extract (PEE) showed the most bioactive extract where, the anti-diabetic activity exhibited by 100mg of PEE extract was 74.38% relative to metformin. It also showed a significant anti-proliferative activity against MCF-7 (IC50=2.35µg), Hela (IC50=3.85µg) and HEPG-2 (IC50=9.54µg) compared with Doxorubicin as reference drug. The hepatoprotective activity of the PEE was evidenced by a significant decrease in the liver function enzymes, i.e. AST, ALT and ALP by 29.18%, 28.26%, and 34.11%, respectively, using silymarin as the reference drug, compared to their concentration levels in an untreated group with liver damage induced by CCl₄. Based on the above outcomes, further phytochemical investigation including GC/MS analysis of its fractions, GLC analysis of its sterol fraction, column chromatography and TLC fractionation of PEE to separate its bioactive compounds were conducted.
{"title":"Bioactivities and Phytochemical Studies of Acrocarpus fraxinifolius Bark Wight Arn","authors":"H. El-Rafie, A. Zeid, A. Sleem, Rs Mohammed","doi":"10.21608/ejchem.2019.15114.1917","DOIUrl":"https://doi.org/10.21608/ejchem.2019.15114.1917","url":null,"abstract":"Acrocarpus is a genus of flowering plants in the legume family Fabaceae which considered as a large and economically important family. This study aimed to carry out the biological activity screening on the total ethanol and successive extracts of Acrocarpus fraxinofolius (A. fraxinofolius) bark, for the first time. The biological activity studied embraced, management of diabetes in alloxan induced diabetic rats, cytotoxic activity against four human tumor cell lines and hepatoprotective activity against CCl4-induced hepatotoxicity in rats and the activity was studied by assaying the serum marker enzymes like AST, ALT, and ALP. Concerning this, the petroleum ether extract (PEE) showed the most bioactive extract where, the anti-diabetic activity exhibited by 100mg of PEE extract was 74.38% relative to metformin. It also showed a significant anti-proliferative activity against MCF-7 (IC50=2.35µg), Hela (IC50=3.85µg) and HEPG-2 (IC50=9.54µg) compared with Doxorubicin as reference drug. The hepatoprotective activity of the PEE was evidenced by a significant decrease in the liver function enzymes, i.e. AST, ALT and ALP by 29.18%, 28.26%, and 34.11%, respectively, using silymarin as the reference drug, compared to their concentration levels in an untreated group with liver damage induced by CCl₄. Based on the above outcomes, further phytochemical investigation including GC/MS analysis of its fractions, GLC analysis of its sterol fraction, column chromatography and TLC fractionation of PEE to separate its bioactive compounds were conducted.","PeriodicalId":23793,"journal":{"name":"World Academy of Science, Engineering and Technology, International Journal of Pharmacological and Pharmaceutical Sciences","volume":"6 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88252241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-28DOI: 10.4172/0975-0851-C1-031
Riddhi Shukla, Rajeshri D. Patel, Prakruti Buch, Tejas P Sharma, M. Raval, N. Sheth
{"title":"Paradigm Shift in Classical Drug Research: Challenges to Mordern Pharmaceutical Sciences","authors":"Riddhi Shukla, Rajeshri D. Patel, Prakruti Buch, Tejas P Sharma, M. Raval, N. Sheth","doi":"10.4172/0975-0851-C1-031","DOIUrl":"https://doi.org/10.4172/0975-0851-C1-031","url":null,"abstract":"","PeriodicalId":23793,"journal":{"name":"World Academy of Science, Engineering and Technology, International Journal of Pharmacological and Pharmaceutical Sciences","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79505460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-02-16DOI: 10.26226/morressier.57ea3d6ad462b8028d88e325
Rowan E. Moore, K. Scheffler, Eugen Damoc, Jennifer N. Sutton, A. Bailey, S. Houel, Simon Cubbon, J. Josephs
{"title":"Full Characterization of Heterogeneous Antibody Samples under Denaturing and Native Conditionson a Hybrid Quadrupole-Orbitrap Mass Spectrometer","authors":"Rowan E. Moore, K. Scheffler, Eugen Damoc, Jennifer N. Sutton, A. Bailey, S. Houel, Simon Cubbon, J. Josephs","doi":"10.26226/morressier.57ea3d6ad462b8028d88e325","DOIUrl":"https://doi.org/10.26226/morressier.57ea3d6ad462b8028d88e325","url":null,"abstract":"","PeriodicalId":23793,"journal":{"name":"World Academy of Science, Engineering and Technology, International Journal of Pharmacological and Pharmaceutical Sciences","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78269354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-12DOI: 10.18203/2319-2003.ijbcp20170326
Shahnaz Haque, Anandi Shukla, Sunita Singh, A. Kem
Background: This study was designed to assess the treatment satisfaction between Sitagliptin versus Pioglitazone added to Metformin in patients with type 2 diabetes mellitus (T2DM). Methods: We conducted a prospective, open label, randomized, parallel group study in SIMS, Hapur, U.P. Eligible patients fulfilling inclusion criteria were randomized into two groups having 25 patients in each group using tab Sitagliptin 100mg,tab Pioglitazone 30mg added to ongoing tab Metformin (500mg) therapy for 16 weeks. The follow-up visits were on weeks 4, 12 and 16. Results: 16 weeks later, addition of Sitagliptin 100mg compared to that of Pioglitazone 30mg to ongoing Metformin therapy provided similar glycosylated haemoglobin (HbA1c) lowering efficacy in patients with T2DM with inadequate glycemic control on metformin monotherapy. Change in HbA1c in group1 was -0.656±0.21% (p<0.0001) whereas in group 2 was -0.748±0.35% (p<0.0001). Hence decrease in HbA1c from baseline was more in group2.Both treatments were well tolerated with negligible risk of hypoglycaemia. Weight loss was observed with Sitagliptin in contrast to weight gain seen in Pioglitazone. Conclusions: In this study, Sitagliptin 100 mg along with metformin therapy in comparison to pioglitazone 30 mg plus metformin therapy was effective, well-tolerated and improved glycemic control in both the groups. Addition of pioglitazone had cause oedema and weight gain to the patients whereas sitagliptin caused weight loss in its patients.
{"title":"[Keynote Talk]: Treatment Satisfaction and Safety of Sitagliptin versus Pioglitazone in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Monotherapy","authors":"Shahnaz Haque, Anandi Shukla, Sunita Singh, A. Kem","doi":"10.18203/2319-2003.ijbcp20170326","DOIUrl":"https://doi.org/10.18203/2319-2003.ijbcp20170326","url":null,"abstract":"Background: This study was designed to assess the treatment satisfaction between Sitagliptin versus Pioglitazone added to Metformin in patients with type 2 diabetes mellitus (T2DM). Methods: We conducted a prospective, open label, randomized, parallel group study in SIMS, Hapur, U.P. Eligible patients fulfilling inclusion criteria were randomized into two groups having 25 patients in each group using tab Sitagliptin 100mg,tab Pioglitazone 30mg added to ongoing tab Metformin (500mg) therapy for 16 weeks. The follow-up visits were on weeks 4, 12 and 16. Results: 16 weeks later, addition of Sitagliptin 100mg compared to that of Pioglitazone 30mg to ongoing Metformin therapy provided similar glycosylated haemoglobin (HbA1c) lowering efficacy in patients with T2DM with inadequate glycemic control on metformin monotherapy. Change in HbA1c in group1 was -0.656±0.21% (p<0.0001) whereas in group 2 was -0.748±0.35% (p<0.0001). Hence decrease in HbA1c from baseline was more in group2.Both treatments were well tolerated with negligible risk of hypoglycaemia. Weight loss was observed with Sitagliptin in contrast to weight gain seen in Pioglitazone. Conclusions: In this study, Sitagliptin 100 mg along with metformin therapy in comparison to pioglitazone 30 mg plus metformin therapy was effective, well-tolerated and improved glycemic control in both the groups. Addition of pioglitazone had cause oedema and weight gain to the patients whereas sitagliptin caused weight loss in its patients.","PeriodicalId":23793,"journal":{"name":"World Academy of Science, Engineering and Technology, International Journal of Pharmacological and Pharmaceutical Sciences","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82203682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-23DOI: 10.1158/1538-7445.AM2016-1082
J. Quintana, I. Stoner, M. Tackett, G. Doran, Conor Rafferty, A. Windemuth, J. Tytell, D. Pregibon
To address the needs for circulating miRNA biomarker validation, we developed the Multiplexed Circulating microRNA assay. This assay enables the detection of up to 68 microRNA targets per sample in 96-well format with readout on standard flow cytometers and analysis with an included bioinformatics software package. The Circulating microRNA assay combines particle-based multiplexing, using patented Firefly hydrogel particles, with single-step RT-PCR signal amplification using universal primers. Thus, the Circulating microRNA assay leverages PCR sensitivity while eliminating the need for separate reverse transcription reactions and mitigating amplification biases introduced by target-specific qPCR. Furthermore, the ability to multiplex targets in each well eliminates the need to split valuable samples into multiple reactions. Results from the Circulating microRNA assay are displayed and interpreted using our included Firefly Analysis Workbench, which allows visualization, normalization, and export of experimental data with only a few mouse clicks. To aid discovery and validation of biomarkers, we have generated fixed panels for Oncology, Cardiology, Neurology, Immunology, and Liver Toxicology. These carefully curated panels include hemolysis markers to assess sample quality, as well as critical normalization factors. Here we present the data from several studies investigating circulating and tumor microRNA profiles using the Firefly Circulating microRNA Assay Fixed Panels. Together, this novel combination of bioinformatics tools and multiplexed, high-sensitivity assays enables rapid discovery and validation of microRNA biomarker signatures from fluid specimens. Citation Format: Jessica Tytell, Issac Stoner, Michael Tackett, Graeme Doran, Conor Rafferty, Andreas Windemuth, Daniel Pregibon. High-throughput,purification-free, multiplexed profiling of circulating miRNA for discovery,validation, and diagnostics. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1082.
为了满足循环microRNA生物标志物验证的需求，我们开发了多重循环microRNA测定。该检测方法可检测多达68个microRNA靶标，每个样品96孔格式，在标准流式细胞仪上读出，并附带生物信息学软件包进行分析。循环microRNA检测结合了基于颗粒的多路复用，使用专利的Firefly水凝胶颗粒，以及使用通用引物的单步RT-PCR信号扩增。因此，循环microRNA分析利用PCR敏感性，同时消除了对单独的逆转录反应的需要，并减轻了靶标特异性qPCR引入的扩增偏差。此外，在每口井中多重目标的能力消除了将有价值的样品分成多个反应的需要。循环microRNA分析的结果显示和解释使用我们的萤火虫分析工作台，它允许可视化，规范化和导出实验数据，只需点击几下鼠标。为了帮助发现和验证生物标志物，我们已经为肿瘤学、心脏病学、神经学、免疫学和肝脏毒理学制作了固定的面板。这些精心策划的面板包括溶血标志物，以评估样品质量，以及关键的正常化因素。在这里，我们介绍了几项研究的数据，这些研究使用萤火虫循环microRNA测定固定板调查循环和肿瘤microRNA谱。总之，这种生物信息学工具和多路、高灵敏度分析的新组合可以快速发现和验证流体标本中的microRNA生物标志物特征。引文格式:Jessica Tytell, Issac Stoner, Michael Tackett, Graeme Doran, Conor Rafferty, Andreas Windemuth, Daniel Pregibon。用于发现、验证和诊断的循环miRNA的高通量、无纯化、多路分析。[摘要]。摘自:第107届美国癌症研究协会年会论文集;2016年4月16-20日;新奥尔良，洛杉矶。费城(PA): AACR;癌症杂志2016;76(14增刊):摘要第1082期。
{"title":"High-Throughput, Purification-Free, Multiplexed Profiling of Circulating miRNA for Discovery, Validation, and Diagnostics","authors":"J. Quintana, I. Stoner, M. Tackett, G. Doran, Conor Rafferty, A. Windemuth, J. Tytell, D. Pregibon","doi":"10.1158/1538-7445.AM2016-1082","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2016-1082","url":null,"abstract":"To address the needs for circulating miRNA biomarker validation, we developed the Multiplexed Circulating microRNA assay. This assay enables the detection of up to 68 microRNA targets per sample in 96-well format with readout on standard flow cytometers and analysis with an included bioinformatics software package. The Circulating microRNA assay combines particle-based multiplexing, using patented Firefly hydrogel particles, with single-step RT-PCR signal amplification using universal primers. Thus, the Circulating microRNA assay leverages PCR sensitivity while eliminating the need for separate reverse transcription reactions and mitigating amplification biases introduced by target-specific qPCR. Furthermore, the ability to multiplex targets in each well eliminates the need to split valuable samples into multiple reactions. Results from the Circulating microRNA assay are displayed and interpreted using our included Firefly Analysis Workbench, which allows visualization, normalization, and export of experimental data with only a few mouse clicks. To aid discovery and validation of biomarkers, we have generated fixed panels for Oncology, Cardiology, Neurology, Immunology, and Liver Toxicology. These carefully curated panels include hemolysis markers to assess sample quality, as well as critical normalization factors. Here we present the data from several studies investigating circulating and tumor microRNA profiles using the Firefly Circulating microRNA Assay Fixed Panels. Together, this novel combination of bioinformatics tools and multiplexed, high-sensitivity assays enables rapid discovery and validation of microRNA biomarker signatures from fluid specimens. Citation Format: Jessica Tytell, Issac Stoner, Michael Tackett, Graeme Doran, Conor Rafferty, Andreas Windemuth, Daniel Pregibon. High-throughput,purification-free, multiplexed profiling of circulating miRNA for discovery,validation, and diagnostics. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1082.","PeriodicalId":23793,"journal":{"name":"World Academy of Science, Engineering and Technology, International Journal of Pharmacological and Pharmaceutical Sciences","volume":"73 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74115541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-04-08DOI: 10.18143/JISANH_V3I1_861
A. Upaganlawar, C. Upasani
The present study was design to screen the neuroprotective and antioxidant activity of corosolic acid in painful diabetic neuropathy (DN). Diabetes was induced in rats by single dose of STZ (60mg/kg, i.p). Diabetic rats were tested week for the development of pain, at 6th week the rats developed significant neuropathic pain. They were divided into different groups and treated with Corosolic acid (2 and 4 mg/kg, p.o) for further two weeks. Pain was assessed in the diabetic rats by mechano-tactil allodynia, mechanical hyperalgesia and cold allodynia. At the end of treatment period rats were scarified and biochemical changes such as plasma glucose level, endogenous antioxidants (Lipid peroxidation, reduced glutathione, superoxide dismutase and catalase) in sciatic nerve were evaluated. Further Na+/K+ ATPase and nitric oxide content was also evaluated. Treatment with corosolic acid for two weeks restored the altered body weight and elevated blood sugar level. Further corosolic acid showed dose dependent reduction in pain in neuropathic animals. The level of endogenous antioxidants enzymes, Na+/K+ ATPase and nitric oxide were significantly prevented. In conclusion. The result of the present study suggests the antidiabetic, antioxidant and neuroprotectieve property of corosolic acid in diabetic rats with neuropathic pain.
{"title":"Supplementation of Corosolic Acid Prevents the Development of Neuropathic Pain in Streptozotocin Induced Diabetic Rats","authors":"A. Upaganlawar, C. Upasani","doi":"10.18143/JISANH_V3I1_861","DOIUrl":"https://doi.org/10.18143/JISANH_V3I1_861","url":null,"abstract":"The present study was design to screen the neuroprotective and antioxidant activity of corosolic acid in painful diabetic neuropathy (DN). Diabetes was induced in rats by single dose of STZ (60mg/kg, i.p). Diabetic rats were tested week for the development of pain, at 6th week the rats developed significant neuropathic pain. They were divided into different groups and treated with Corosolic acid (2 and 4 mg/kg, p.o) for further two weeks. Pain was assessed in the diabetic rats by mechano-tactil allodynia, mechanical hyperalgesia and cold allodynia. At the end of treatment period rats were scarified and biochemical changes such as plasma glucose level, endogenous antioxidants (Lipid peroxidation, reduced glutathione, superoxide dismutase and catalase) in sciatic nerve were evaluated. Further Na+/K+ ATPase and nitric oxide content was also evaluated. Treatment with corosolic acid for two weeks restored the altered body weight and elevated blood sugar level. Further corosolic acid showed dose dependent reduction in pain in neuropathic animals. The level of endogenous antioxidants enzymes, Na+/K+ ATPase and nitric oxide were significantly prevented. In conclusion. The result of the present study suggests the antidiabetic, antioxidant and neuroprotectieve property of corosolic acid in diabetic rats with neuropathic pain.","PeriodicalId":23793,"journal":{"name":"World Academy of Science, Engineering and Technology, International Journal of Pharmacological and Pharmaceutical Sciences","volume":"113 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82716109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Since time immemorial, plants have been used by several communities to treat a large number of diseases. Numerous studies on the pharmacology of medicinal plants have been done. Medicinal plants constitute a potential source for the production of new medicines and may complement conventional antimicrobials and probably decrease health costs. Phytochemical compounds in plants are known to be biologically active aiding, for example, as antioxidants and antimicrobials. The overwhelming challenge of drug resistance has resulted in an increasing trend towards using medicinal plants to treat various diseases, especially in developing countries. Species of the genus Tulbaghia has been widely used in traditional medicine to treat various ailments such rheumatism, fits, fever, earache, tuberculosis etc. It is believed that the species possess several therapeutic properties. This paper evaluates some of the biological activities of the genus Tulbaghia. It is evident from current literature that Tulbaghia violacea is the most promising species. The other species of Tulbaghia still require further studies to ascertain their medicinal potential. Key words: Tulbaghia, antioxidants, antimicrobial, anticancer, biological activities.
{"title":"Biological Activities of Species in the Genus Tulbaghia: A Review","authors":"S. Takaidza, M. Pillay, F. Mtunzi","doi":"10.5897/AJB2015.14970","DOIUrl":"https://doi.org/10.5897/AJB2015.14970","url":null,"abstract":"Since time immemorial, plants have been used by several communities to treat a large number of diseases. Numerous studies on the pharmacology of medicinal plants have been done. Medicinal plants constitute a potential source for the production of new medicines and may complement conventional antimicrobials and probably decrease health costs. Phytochemical compounds in plants are known to be biologically active aiding, for example, as antioxidants and antimicrobials. The overwhelming challenge of drug resistance has resulted in an increasing trend towards using medicinal plants to treat various diseases, especially in developing countries. Species of the genus Tulbaghia has been widely used in traditional medicine to treat various ailments such rheumatism, fits, fever, earache, tuberculosis etc. It is believed that the species possess several therapeutic properties. This paper evaluates some of the biological activities of the genus Tulbaghia. It is evident from current literature that Tulbaghia violacea is the most promising species. The other species of Tulbaghia still require further studies to ascertain their medicinal potential. Key words: Tulbaghia, antioxidants, antimicrobial, anticancer, biological activities.","PeriodicalId":23793,"journal":{"name":"World Academy of Science, Engineering and Technology, International Journal of Pharmacological and Pharmaceutical Sciences","volume":"79 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81326474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study investigate the antioxidative properties and the ability of aqueous, ethanol and ethyl acetate extracts from Ocimum gratissimum (OG) leaves to inhibit some pro-oxidants (Fe and sodium nitroprusside) induced lipid peroxidation in rat’s liver homogenates in vitro. The ability of the extracts to inhibit 25 μM FeSO4 and 7.0 μM sodium nitroprusside induced lipid peroxidation in isolated rat’s liver was determined. The results of the study revealed that both pro-oxidants caused a significantly decrease in (p<0.05) accumulation of lipid peroxides. However, aqueous extract of Ocimum gratissimum shows a high ability to inhibit lipid production in the liver induced with SNP than Fe. Ethanol and ethyl acetate extract of Ocimum gratissimum which shows a high ability to inhibit lipid production more when induced with Fe than SNP. However, ethyl acetate fraction of Ocimum gratissimum shows a higher inhibitory effect on both Fe and SNP induced lipid peroxidation in rat’s liver. This might be as a result of its significantly higher extractable phytochemicals. Therefore, Fe II and sodium nitroprusside induced oxidative stress could be managed by dietary intake of Ocimum gratissimum leaves.
{"title":"Extracts of Ocimum gratissimum Leaves Inhibits Fe2+ and Sodium Nitroprusside Induced Oxidative Stress in Rat Liver","authors":"O. Ojo, O. Oloyede","doi":"10.7897/2277-4572.05318","DOIUrl":"https://doi.org/10.7897/2277-4572.05318","url":null,"abstract":"This study investigate the antioxidative properties and the ability of aqueous, ethanol and ethyl acetate extracts from Ocimum gratissimum (OG) leaves to inhibit some pro-oxidants (Fe and sodium nitroprusside) induced lipid peroxidation in rat’s liver homogenates in vitro. The ability of the extracts to inhibit 25 μM FeSO4 and 7.0 μM sodium nitroprusside induced lipid peroxidation in isolated rat’s liver was determined. The results of the study revealed that both pro-oxidants caused a significantly decrease in (p<0.05) accumulation of lipid peroxides. However, aqueous extract of Ocimum gratissimum shows a high ability to inhibit lipid production in the liver induced with SNP than Fe. Ethanol and ethyl acetate extract of Ocimum gratissimum which shows a high ability to inhibit lipid production more when induced with Fe than SNP. However, ethyl acetate fraction of Ocimum gratissimum shows a higher inhibitory effect on both Fe and SNP induced lipid peroxidation in rat’s liver. This might be as a result of its significantly higher extractable phytochemicals. Therefore, Fe II and sodium nitroprusside induced oxidative stress could be managed by dietary intake of Ocimum gratissimum leaves.","PeriodicalId":23793,"journal":{"name":"World Academy of Science, Engineering and Technology, International Journal of Pharmacological and Pharmaceutical Sciences","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76321379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Agrawal, Pravina Gurjar, Supriya Bhide, R. Gaud
{"title":"Solid Lipid Nanoparticles of Levamisole Hydrochloride","authors":"S. Agrawal, Pravina Gurjar, Supriya Bhide, R. Gaud","doi":"10.35652/IGJPS.2014.14","DOIUrl":"https://doi.org/10.35652/IGJPS.2014.14","url":null,"abstract":"","PeriodicalId":23793,"journal":{"name":"World Academy of Science, Engineering and Technology, International Journal of Pharmacological and Pharmaceutical Sciences","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77376936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：